Previous Close | 100.06 |
Open | 100.72 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 100.56 - 102.70 |
52 Week Range | 80.95 - 106.66 |
Volume | |
Avg. Volume | 2,675,843 |
Market Cap | 128.416B |
Beta (5Y Monthly) | 0.44 |
PE Ratio (TTM) | 20.87 |
EPS (TTM) | 4.90 |
Earnings Date | Apr 26, 2022 - May 02, 2022 |
Forward Dividend & Yield | 3.33 (3.34%) |
Ex-Dividend Date | May 06, 2022 |
1y Target Est | 110.74 |
The go-ahead covers a chronic inflammatory disease for which the Food and Drug Administration has never before approved a treatment.
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this c
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date